Search

Displaying results 901 - 910 of 5756 in total
  1. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada.

  2. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [L44918,L44948] It received a similar approval in the EU in September 2023.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  3. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  4. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of

  5. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (I...

  6. Drug

    Hydroxyproline

    go.drugbank.com/drugs/DB08847
    Approved

    Hydroxyproline is a neutral heterocyclic protein amino acid. It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis. Therapeutic...

    Mixtures: Ouhi Cell Power No 1 Essence, Ouhi Cell Power No 1 Eye
  7. Drug

    IL15-NK Cell

    go.drugbank.com/drugs/DB15725
    Investigational

    Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.

    Synonyms: IL15-NK Cell
  8. Drug

    Mepyramine

    go.drugbank.com/drugs/DB06691
    ApprovedVet approved

    Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination produc...

    Mixtures: Viravan P, Glen PECategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chronic cough (UCC) when no

    Categories: P-glycoprotein substrates
  10. Drug

    Retezorogant

    go.drugbank.com/drugs/DB21592
    Experimental

    Retezorogant has a monoisotopic molecular weight of 420.22 Da. … The usage of the INN stem '-rogant' in the name indicates that Retezorogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist.